Shannon Fitzgerald
Family · Allison Park, PANPI 1356717607
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $288,389 of the $369,832 with a category attached, or 78.0%. Seagen Inc. accounts for 98.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $209,758 and has fallen 97.3% since, to $5,724 in 2025. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 843 payments — averaging $438.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$363K
- Indivior Inc.$6K
- Genmab U.S., Inc.$315
- Braeburn Inc.$170
- Bayer$85
- Eisai Inc.$82
- plus $51 from 1 others
What the payments were for
- Consulting fees$288,38978%
- Speaking & faculty fees$2,8481%
- Travel & lodging$72,04119%
- Food & beverage$6,4092%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 793 | $363,327 |
| Indivior Inc. | 33 | $5,802 |
| Genmab U.S., Inc. | 3 | $315 |
| Braeburn Inc. | 9 | $170 |
| Bayer | 1 | $85 |
| Eisai Inc. | 1 | $82 |
| Orexo US, Inc. | 3 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$369,832 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 321 | $47,547 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $4,947 |
| Bupropion Hcl SrBupropion Hcl | 13 | $204 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $139 |
| Citalopram HbrCitalopram Hydrobromide | 14 | $61 |
| Hydroxyzine Hcl | 16 | $33 |
| Trazodone Hcl | 14 | $32 |
| Clonazepam | 13 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $5,802 | $4,94714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Allison Park
- Kathleen ScholzPittsburgh$397K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
- Anne CalvaresiPhiladelphia$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.